Characteristic | Overall (N = 130)a | Patients with best response of SD (n = 32) |
---|---|---|
Age, median (range), y | 61 (20–83) | 61.5 (24–79) |
ECOG performance statusb | ||
0 | 46 (35) | 10 (31) |
1 | 66 (51) | 17 (53) |
2 | 17 (13) | 5 (16) |
International Prognostic Index, n (%) | ||
<2 | 31 (24) | 7 (22) |
≥2 | 99 (76) | 25 (78) |
PTCL subtype based on central review, n (%) | ||
PTCL-NOS | 69 (53) | 16 (50) |
AITL | 27 (21) | 8 (25) |
ALK-1-negative ALCL | 21 (16) | 5 (16) |
Other | 13 (10)c | 3 (9)d |
Stage III/IV at diagnosis, n (%) | 91 (70) | 20 (63) |
Number of prior therapies, n (%) | ||
1 | 38 (29) | 13 (41) |
2 | 44 (34) | 11 (34) |
3 | 19 (15) | 3 (9) |
4 | 15 (12) | 4 (13) |
>4 | 14 (11) | 1 (3) |
Type of prior therapy, n (%) | ||
Chemotherapy | 129 (99) | 31 (97) |
Monoclonal antibody therapy | 20 (15) | 3 (9) |
Other immunotherapy | 14 (11) | 1 (3) |
Radiation | 31 (24) | 8 (25) |
ASCT | 21 (16) | 3 (9) |
Refractory to most recent therapy, n (%) | 49 (38) | 8 (25) |